Results 31 to 40 of about 35,850 (218)

HPV vaccine development after more than ten years approval

Majalah Obstetri dan Ginekologi, 2020
At present, ten years have passed since the human papillomavirus (HPV) vaccine was first approved for use in humans. Research related to HPV vaccine, both in terms of effectiveness and immugenicity in its development, has been widely carried out, such as
Brahmana Askandar
doaj   +1 more source

Self‐Assembly of Antigenic Peptide Nanofibrils Templates the Growth of Silica Nanoparticles for Nanovaccines

Advanced Science, EarlyView.
Antigenic peptides Aβ42 and E7 self‐assemble into nanofibrils; APTES and TEOS induce SiO2 NP formation on these fibrils to form SiO2@fibril nanovaccines, which activate BMDCs in vitro. In vivo, SiO2@Aβ42 fibril nanovaccines alleviate AD symptoms and clear Aβ42 plaques in APP/PS1 mice, and SiO2@E7 fibril nanovaccines inhibit tumor growth and promote ...
Xuecheng Yang, Min Li, Zhiying Yao, Yu Hu, Zhili Wang, Wendi Shi, Bingbing Sun   +6 more
wiley   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

Using the precaution adoption process model to clarify human papillomavirus vaccine hesitancy in canadian parents of girls and parents of boys

Human Vaccines & Immunotherapeutics, 2019
Background: Achieving optimal human papillomavirus (HPV) vaccine uptake can be delayed by parents’ HPV vaccine hesitancy, which is as a multi-stage intention process rather than a dichotomous (vaccinated/not vaccinated) outcome.
Ovidiu Tatar, Gilla K. Shapiro, Samara Perez, Kristina Wade, Zeev Rosberger   +4 more
doaj   +1 more source

Human papillomavirus (HPV) vaccination and factors related to intention to obtain the vaccine among young college women in Thailand [PDF]

Journal of Health Research, 2018
Purpose - Most cervical cancers are caused by genital human papillomavirus (HPV). However, it can be prevented if females receive an HPV vaccine. Nevertheless, there is limited evidence of HPV vaccination and predictors of intention to obtain the vaccine
Nop T. Ratanasiripong, Sirinat Sri-Umporn, Duangrat Kathalae, Suda Hanklang, Paul Ratanasiripong   +4 more
doaj   +1 more source

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, EarlyView.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

The influence of affect on HPV vaccine decision making in an HPV vaccine naïve college student population

Preventive Medicine Reports, 2020
The HPV vaccine is recommended for all adolescents starting at age 11, but coverage is low, especially in the young adult population. The CDC is prioritizing catch-up vaccination and has expanded recommendations for all young adults to age 26.
Lynne B. Klasko-Foster, Sarahmona Przybyla, Heather Orom, Elizabeth Gage-Bouchard, Marc T. Kiviniemi   +4 more
doaj   +1 more source

Extended High‐Risk HPV Genotyping With BD Onclarity Enhances Anal Cancer Screening Among High‐Risk Populations: A Cross‐Sectional Study

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background Anal cancer rates are rising among women, immunocompromised individuals, and Men who have sex with Men (MSM), independent of HIV status. While high‐resolution anoscopy remains the diagnostic standard, limited access has increased interest in alternative screening.
Daisy Maharjan, Joshua Waters, Melissa Randolph, Benjamin Shuler, Julie Borum, Sheila Segura   +5 more
wiley   +1 more source

Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination

Human Vaccines & Immunotherapeutics
Thailand introduced a two-dose regimen of bivalent HPV vaccines for Grade 5 schoolgirls, approximately 11 years old, initially piloted in Ayutthaya province in 2014, and nationwide under the National Immunization Program (NIP) in 2017.
Pornjarim Nilyanimit, Preeyaporn Vichaiwattana, Ratchadawan Aeemchinda, Wichan Bhunyakitikorn, Thanawadee Thantithaveewat, Sunanta Seetho, Darunee Phosri, Naiyana Netthip, Nungruthai Suntronwong, Nasamon Wanlapakorn, Yong Poovorawan   +10 more
doaj   +1 more source